Primus Trades Review 2025
-
Updated:
Reason to avoid: No license
Listed Date: October 14, 2018
Top 3 Forex Brokers
Beware Primus Trades is a Non-Regulated Broker. It is NOT SAFE to trade.
Advertising Disclosure
Updated:
Reason to avoid: No license
Listed Date: October 14, 2018
Beware Primus Trades is a Non-Regulated Broker. It is NOT SAFE to trade.
Primus Trades is not a secure Forex broker since it does not hold a license from any worldwide serious Forex authority. Meaning the broker is suspected of being a fraud company since it was not checked for its compliance before establishment, was never monitored in terms of its safety, and may operate the business in any way it wishes.
🗺️ Registered in | No Registration |
🗺️ Type of License | No License |
🛡️ Is Primus Trades safe to trade | No |
🗺️ Recommended Licenses | FCA in UK 🇬🇧 & ASIC in Australia 🇦🇺 |
🖥 Alternative Broker | FP Markets - licensed by ASIC in Australia |
Primus Trades is a broker that specializes on Forex and cryptocurrency trading. The company doesn't provide much information about its terms and conditions, whereas usually, brokers mention the company owner and the regulation details. There is actually regulation info that can be found on the website: "Primus Trades was founded in 2015 as a London-based fund management company regulated by the Cyprus Security and Exchange Commission (CySec)".
Obviously, the company is not licensed by the Cyprus regulatory body or any other agency. We advise avoiding Primus Trades as it has no regulation and no legal right to provide financial services. Instead, we recommend checking the list of the CySec-regulated brokers, as this regulator is well-known and trustworthy. Also, trade only with well-regulated brokers such as UK brokers or brokers in Australia and reliable brokers such as FP Markets and HotForex.
Based on our research, the Primus Trades website is inactive. This means the broker has muted its trading offering and does not operate. However, we recommend avoiding and staying alert in case of any proposals.
No review found...
No news available.